Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
Acq. announced
CC transcript
INTERLEUKIN GENETICS INC (ILIU) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/24/2017 8-K Quarterly results
07/03/2017 8-K Form 8-K - Current report
03/31/2017 8-K Form 8-K - Current report
12/23/2016 8-K Form 8-K - Current report
10/24/2016 8-K Submission of Matters to a Vote of Security Holders
09/30/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Third Amendment to Commercial Lease, by and between the Company and Clematis, LLC"
08/26/2016 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Lender Warrant",
"First Amendment of Venture Loan and Security Agreement, by and among Interleukin Genetics, Inc. and Horizon Credit II LLC, as assignee of Horizon Technology Finance Corporation"
08/01/2016 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant issued to the Purchasers",
"Securities Purchase Agreement, by and among Interleukin and the Purchasers",
"Registration Rights Agreement, by and among Interleukin and the Purchasers",
"INTERLEUKIN GENETICS, INC. ANNOUNCES $5.6 MILLION PRIVATE PLACEMENT FINANCING WALTHAM, MA – August 1, 2016 – Interleukin Genetics, Inc. , a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that it has entered into an agreement with various accredited and institutional investors to raise gross proceeds of approximately $5.6 million in a private placement financing. The syndicate is composed of existing investors, including two leading life sciences investment firms, Bay City Capital and New Enterprise Associates , and Pyxis Innovations Inc., an affiliate of Alticor Inc. , and broad participation among the management team. The investment in Interleukin Genetics consists of the sale and issu..."
11/07/2013 8-K Entry into a Material Definitive Agreement
08/13/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment filed with the Delaware Secretary of State on August 9, 2013",
"INTERLEUKIN GENETICS, INC. 2013 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN"
06/05/2013 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Elimination of the Series A-1 Preferred Stock and Series B Preferred Stock of Interleukin Genetics, Inc."
06/05/2013 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/28/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2013 8-K Entry into a Material Definitive Agreement
01/03/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "INTERLEUKIN GENETICS APPOINTS SCOTT SNYDER AS CHIEF MARKETING OFFICER WALTHAM, MASS. – January 3, 2013 – Interleukin Genetics, Inc. today announced the appointment of Scott Snyder as Chief Marketing Officer. In this role, Scott will spearhead the launch of the company’ s proprietary PST genetic risk panel to guide more effective dental preventive care. Scott will have responsibility for marketing Interleukin’ s professional healthcare tests, including PST and a proprietary test for osteoarthritis progression, and for the Inherent Health brand of health and wellness genetic tests within consumer channels. “I am very pleased to welcome Scott as Interleukin’ s new Chief Marketing Officer and have great confidence that he will drive the next phase of the Company’ s growth,” said Kenneth Kornma..."
12/26/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/30/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Second Amendment, to the Employment Agreement, by and between Interleukin Genetics, Inc. and Kenneth S. Kornman"
11/30/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Amended and Restated Promissory Note under the credit facility with Pyxis Innovations Inc. issued on November 30, 2012",
"Fifth Amendment, to the Amended and Restated Note Purchase Agreement, between Interleukin and Pyxis Innovations Inc"
09/27/2012 8-K Entry into a Material Definitive Agreement
09/20/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement, between Interleukin Genetics, Inc. and Lewis H. Bender"
08/29/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "INTERLEUKIN Genetics ANNOUNCES EXECUTIVE MANAGEMENT CHANGES WALTHAM, Mass. – August 23, 2012 – Interleukin Genetics, Inc. announced today that Lewis H. Bender has resigned as Chief Executive Officer and as a member of the Board of Directors, effective August 23, 2012, in order to pursue other business opportunities. The Board of Directors has appointed Kenneth S. Kornman, DDS, Ph.D., the Company's founder and current President and Chief Scientific Officer, as Chief Executive Officer and as a member of the Board of Directors. Dr. Kornman will also continue his duties as President and Chief Scientific Officer. “On behalf of the Board of Directors of Interleukin, I would like to thank Lew Bender for his significant contributions to Interleukin’ s development and growth and wish him success in..."
08/09/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment filed with the Delaware Secretary of State on August 9, 2012",
"Second annual dental cleaning does not reduce tooth loss in low risk patient population; High risk population benefits from additional care"
07/02/2012 8-K Form 8-K - Current report
04/26/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Amendment, effective as of March 31, 2012, to the Employment Agreement, by and between Interleukin Genetics, Inc. and Kenneth S. Kornman"
04/18/2012 8-K Entered into an underwriting agreement for the issuance and sale of notes
11/10/2011 8-K Form 8-K - Current report
06/22/2011 8-K/A Form 8-K - Current report [amend]
04/20/2011 8-K Form 8-K - Current report
03/21/2011 8-K Form 8-K - Current report
03/16/2011 8-K Resignation/termination of a director
02/16/2011 8-K Form 8-K - Current report
11/12/2010 8-K Form 8-K - Current report
10/04/2010 8-K Form 8-K - Current report
08/17/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy